3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
22
Phase 2
15
Phase 1
10
Phase 1/2
7
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
75
Lung Neoplasms
48
Small Cell Lung Carcinoma
11
Neoplasms
10
NSCLC
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Brain Neoplasms
6
Mesothelioma
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Melanoma
4
Head and Neck Neoplasms
4
Adenocarcinoma of Lung
4
Liver Neoplasms
3
Hematologic Neoplasms
3
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Sarcoma
2
Recurrence
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Laryngeal Neoplasms
2
Interventions
pembrolizumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Thoracic
×
Clear all
NCT01905657
2021-10-06
MK-3475-010
Merck Sharp & Dohme LLC
Phase 2/3
Completed
1,034 enrolled
16 charts